Investor Eye: Israel’s Medical Device Fund Accelmed Seizes On Slow Medtech Investing

NTERVIEWS | by Catherine Longworth | Medtech Insight



Accelmed Partner, Irit Yaniv, is an experienced senior executive in life sciences and former physician who oversees the firm’s investment in early stage Israeli medtech. Over the years, Yaniv says investors’ focus has shifted from medical devices to pharma with fewer VCs specializing in medical devices.

This year, Yaniv will co-chair the Disruptive and Advanced Medical Devices track at MiXiii BIOMED,* Israel’s largest conference for the health care industry, held in Tel Aviv. According to Yaniv, Israel is strong in cardiovascular and metabolic innovation and BIOMED will bring together promising start-ups such as Vectorious Medical Technologies, which is targeting heart failure treatment with the world’s first ‘in-heart microcomputer.’

*MiXiii Biomed is Israel’s leading international life science conference and exhibition, held May 14-16 in Tel Aviv. The conference is the main annual meeting place for representatives of Israel’s health-care industry with their colleagues from around the world. Previous successful conferences hosted over 6,000 industry executives, scientists, physicians, engineers and investors, with approximately 1,000 of the participants coming from over 45 countries.